Edmond DE Rothschild Holding S.A. Purchases 19,374 Shares of Johnson & Johnson $JNJ

Key Points

• Edmond DE Rothschild Holding increased its Johnson & Johnson position by 32.6% in the second quarter, purchasing 19,374 shares and bringing its total holdings to 78,892 shares valued at approximately $20.0 million.
• Institutional investors own 69.55% of J&J, while company insiders have sold 63,972 shares worth $16.25 million over the past three months.
• J&J reported quarterly EPS of $2.90 and revenue of $25.31 billion, exceeding estimates, and declared a quarterly dividend of $1.34 per share. Analysts maintain a consensus “Moderate Buy” rating with an average price target of $268.22.

Edmond DE Rothschild Holding S.A. grew its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 32.6% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 78,892 shares of the company's stock after buying an additional 19,374 shares during the period. Edmond DE Rothschild Holding S.A.'s holdings in Johnson & Johnson were worth $20,036,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in JNJ. State Street Corp lifted its position in Johnson & Johnson by 1.3% in the 4th quarter. State Street Corp now owns 133,869,843 shares of the company's stock valued at $27,704,364,000 after acquiring an additional 1,663,782 shares in the last quarter. Auto Owners Insurance Co increased its holdings in shares of Johnson & Johnson by 22,225.6% in the 4th quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company's stock worth $1,436,633,000 after purchasing an additional 69,108,368 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Johnson & Johnson by 3.1% in the fourth quarter. Geode Capital Management LLC now owns 57,953,747 shares of the company's stock worth $11,967,947,000 after purchasing an additional 1,738,292 shares during the last quarter. Norges Bank purchased a new stake in shares of Johnson & Johnson during the fourth quarter valued at $6,924,523,000. Finally, Wellington Management Group LLP increased its holdings in Johnson & Johnson by 3.8% in the 3rd quarter. Wellington Management Group LLP now owns 25,832,777 shares of the company's stock worth $4,789,914,000 after buying an additional 956,239 shares in the last quarter. Institutional investors own 69.55% of the company's stock.

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Vanessa Broadhurst sold 23,054 shares of the firm's stock in a transaction on Monday, July 20th. The stock was sold at an average price of $251.27, for a total value of $5,792,778.58. Following the transaction, the executive vice president directly owned 23,003 shares of the company's stock, valued at approximately $5,779,963.81. This trade represents a 50.06% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Elizabeth Forminard sold 15,918 shares of Johnson & Johnson stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $257.00, for a total value of $4,090,926.00. Following the transaction, the executive vice president owned 16,994 shares in the company, valued at $4,367,458. This trade represents a 48.37% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 63,972 shares of company stock valued at $16,245,605 over the last three months. Insiders own 0.16% of the company's stock.

Johnson & Johnson Stock Up 2.1%

JNJ stock opened at $271.53 on Wednesday. The company has a market cap of $654.36 billion, a price-to-earnings ratio of 31.46, a P/E/G ratio of 2.54 and a beta of 0.24. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09. The business's 50-day moving average is $260.21 and its two-hundred day moving average is $244.39. Johnson & Johnson has a fifty-two week low of $173.33 and a fifty-two week high of $276.47.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.84 by $0.06. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The business had revenue of $25.31 billion during the quarter, compared to the consensus estimate of $25.06 billion. During the same period in the previous year, the company posted $2.77 EPS. The business's quarterly revenue was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, analysts forecast that Johnson & Johnson will post 11.61 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be issued a dividend of $1.34 per share. This represents a $5.36 dividend on an annualized basis and a yield of 2.0%. The ex-dividend date of this dividend is Tuesday, August 25th. Johnson & Johnson's dividend payout ratio is currently 62.11%.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. Johnson Rice reissued a "buy" rating on shares of Johnson & Johnson in a research report on Monday, August 3rd. Argus set a $300.00 price target on shares of Johnson & Johnson in a research note on Wednesday, July 29th. HSBC set a $290.00 price objective on shares of Johnson & Johnson and gave the company a "buy" rating in a report on Monday, July 6th. Freedom Capital upgraded shares of Johnson & Johnson from a "hold" rating to a "strong-buy" rating in a research report on Thursday, July 16th. Finally, Morgan Stanley raised their target price on shares of Johnson & Johnson from $284.00 to $294.00 and gave the stock an "overweight" rating in a report on Thursday, July 16th. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have given a Hold rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $268.22.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Defensive strength supported the stock. JNJ gained as the broader market weakened, suggesting investors favored its relatively stable healthcare business and dependable dividend. The company has maintained a decades-long dividend-growth streak, making it attractive to income-oriented investors. Johnson & Johnson (JNJ) Rises As Market Takes a Dip: Key Facts
• Positive Sentiment: Upcoming results provide a potential catalyst. Johnson & Johnson will host its third-quarter earnings conference call on October 13. Investors will focus on operating trends, guidance and updates on key risks. Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
• Neutral Sentiment: J&J’s investment portfolio received favorable attention. The company owns stakes in approximately 15 biotechnology and medical-technology companies, with one larger holding standing out because of its market capitalization. The portfolio may offer strategic or financial upside, but it is not currently a major earnings catalyst. Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch.
• Negative Sentiment: One analyst modestly reduced its earnings forecast. Erste Group Bank lowered its 2026 EPS estimate to $11.65 from $11.68, although the revised forecast remains above the broader consensus estimate of $11.61. The small cut is a mild negative signal rather than a material change to the outlook.
• Negative Sentiment: Dividend investors face a longer-term uncertainty. Commentary comparing JNJ with Procter & Gamble highlights a forthcoming corporate event that could threaten the uninterrupted payout record investors associate with J&J. The article does not indicate an immediate dividend reduction, but the issue may temper enthusiasm among income-focused shareholders. Why Procter & Gamble’s Quieter Dividend Outpaces Johnson & Johnson’s Growth Story

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source